经瞳孔温热疗法治疗脉络膜新生血管的临床研究

目的探讨经瞳孔温热疗法(TTT)治疗老年性黄斑变性(AMD)及高度近视患者脉络膜新生血管(CNV)的临床疗效及安全性。方法分别对经眼底血管造影证实有经典型或隐匿型CNV的33例37眼AMD或高度近视患者进行TTT治疗。TTT各光斑平均功率密度为(18.32±2.23)W/cm2。定期随访视力、眼底等,平均随访(3.7±2.3)个月(1～7个月)。结果经过1次或多次TTT治疗,17眼(45.9%)症状减轻或消失;视力稳定或提高者32眼(86.5%),下降≥1行者5眼(13.5%);7眼于TTT过程中视网膜出血增加,3眼随访过程中出现其他部位的新鲜出血。在行造影复查的患者(22例22眼)中,14眼(63.6%)渗漏减轻或消失。结论TTT治疗CNV是一种安全、有效的方法,但其疗效的最终评价以及激光参数的选择依据等需要进一步大样本、长时间的临床研究。     

经瞳孔温热疗法治疗老年黄斑变性所致黄斑中心凹下脉络膜新生血管的长期观察

目的:评价经瞳孔温热疗法(TTT)治疗年龄相关性黄斑变性(AMD)所致黄斑中心凹下脉络膜新生血管(CNV)的长期疗效。方法:AMD所致黄斑中心凹下脉络膜新生血管14例14眼。平均年龄67.1岁。记录详尽的眼科检查结果,拍摄彩色眼底相,并行黄斑部光学相干断层成像(OCT)检查。在初诊及随后的复诊中行眼底荧光素血管造影和吲哚青绿血管造影。TTT的治疗参数为:时间1min,光斑大小2 ~3mm,激光能量650 ~800mW。随诊时间5 ~64mo,平均28.6mo。结果:在14眼中,典型性CNV有10眼,典型为主性有2眼,1眼为少量典型性,1型隐匿性CNV有1眼。共4例患者出现治疗后出血,均在短期内吸收。有1眼在治疗后立刻出现了黄斑无灌注区。多数患眼在随诊中可见渗出逐渐减少。在平均28.6mo的随诊中,14只患眼,有5眼视力提高,8眼保持稳定,1眼视力下降。结论:经瞳孔温热疗法在AMD患者中能封闭黄斑中心凹下的CNV,促进网膜下积液的迅速吸收,从而稳定患者的视力。它可以作为一种治疗典型和典型为主性黄斑中心凹下脉络膜新生血管的激光治疗手段。     

经瞳孔温热疗法治疗老年性黄斑变性的疗效观察

目的 观察经瞳孔温热疗法(transpupillary thermotherapy,TTT)治疗渗出型老年性黄斑变性(age—related macular degeneration，AMD)隐匿型脉络膜新生血管(choroidal neovascularization，CNV)的效果。方法 对28例34眼经眼底荧光血管造影(fundus fluorescein angiography，FFA)及吲哚青绿血管造影(indocyanine green angiography，ICGA)确诊的继发于渗出型AMD的隐匿型CNV行TTT治疗，并主要以视力、眼底检查、FFA及ICGA改变为指标，评价TTT治疗渗出型AMD的效果。结果 随访3～20个月，平均6.65个月，视力提高19眼，视力稳定13眼，视力下降2眼，视网膜水肿基本消退6眼，水肿明显减轻21眼，水肿无明显变化5眼，2眼水肿加重，出血吸收22眼，8眼出血减少，出血无明显变化者2例，另有2眼发生少量新鲜视网膜深层出血，第1次治疗后复查FFA及ICGA，10眼CNV消失，19眼CNV渗漏减轻，3眼无明显变化，2眼CNV增大。结论 TTT治疗可使大部分AMD患者视力稳定或提高，是一种极具潜力的治疗方式，但对其确切疗效的评价。尚需与自然病程及其他治疗方法对比。     

经瞳孔温热疗法治疗脉络膜新生血管

目的 初步观察TTT激光治疗脉络膜新生血管的疗效。方法 23例24眼CNV行TTT（transpupillary thermotherapy，TTT）治疗，根据CNV（choroidal neovascularization，CNV）的大小选择不同的光斑大小和能量，照射时间为1分钟。结果 24眼CNV经TTT治疗后，大部分患者黄斑出血、渗出、水肿减轻或吸收，FFA显示大多数CNV渗漏减少或停止，原CNV瘢痕化，但视力无明显提高。结论 TTT盯治疗脉络膜新生血管有效，但还需要更多的病例来评价治疗效果。     

经瞳孔温热疗法治疗黄斑部脉络膜新生血管

目的探讨经瞳孔温热疗法(transpupillary thermotherapy,TTT)治疗黄斑部脉络膜新生血管膜(choroidal neovascularization,CNV)的疗效.方法经眼底荧光血管检查证实的各原因所致的黄斑部CNV患者27例30眼,其中老年黄斑变性9例11眼,高度近视12例12眼,中心性渗出性脉络膜视网膜炎(简称"中渗")5例5眼,血管条纹症1例,双眼.于2000年6月～2001年9月行TTT治疗,治疗采用IRIS半导体激光,波长810nm,光斑根据CNV病灶大小0.5～3.0 mm,能量180～350 mW,时间60s,治疗后病灶颜色不变或呈淡灰色.随访期8～24个月.结果视力提高2行以上者6眼,占20%,均为中渗或高度近视眼;21眼视力改变不超过2行,占70%;3眼视力下降2行,占10%.19眼于术后复查荧光血管造影,CNV有不同程度的减小或闭塞.结论TTT对多种原因所致的黄斑部CNV均有稳定作用,其作用可持续较长时间.治疗参数因患者眼底色素含量不同而有所差异.最终治疗效果与治疗前病程、CNW的位置及治疗参数的适度有关.     

经瞳孔温热疗法治疗年龄相关性黄斑变性

年龄相关性黄斑变性（AMD）是老年人致盲的常见原因。根据其临床表现可分为干性和湿性。湿性AMD以视网膜色素上皮（RPE）下有活跃的脉络膜新生血管（CNV）为主要特征，而引起视力下降的主要原因是CNV引起的黄斑区反复出血、渗出、瘢痕改变，视力预后极差。经瞳孔温热疗法（TTT）是一种治疗继发于AMD的CNV的较新方法，采用直径可调节的大光斑，穿透深的激光连续照射，使靶组织缓慢升温，在消除CNV病灶的同时又相对保存病变表面视网膜的结构和功能。就TTT治疗AMD的应用发展、特点、临床疗效、治疗方法以及可能出现的并发症等作一综述。     

经瞳孔温热疗法治疗年龄相关性黄斑变性

经瞳孔温热疗法(TTT)是近年来应用于脉络膜新生血管(CNV)治疗的一种新方法。本文对12例12眼AMD患者行TTT后的近期疗效作初步分析。     

经瞳孔温热疗法治疗高度近视性脉络膜新生血管

目的通过分析经瞳孔温热疗法（TTT）治疗高度近视性脉络膜新生血管（CNV）的临床特点和不同影像学表现,以评估TTT疗法对治疗高度近视性CNV的安全性的适应范围。方法荧光素眼底血管造影（FFA）确诊的高度近视性CNV患者24例（25只眼）,采用810nm半导体激光治疗。其中典型性CNV者17只眼,隐匿性CNV者6只眼,混合性（微小典型性）CNV者2只眼。按CNV发病部位分为旁中心凹（中心凹外200～500μm）CNV者10只眼,黄斑区（中心凹50μm外血管弓内）CNV者15只眼。治疗后1个月开始随访,治疗次数1～3次,随访时间6～22个月不等,平均9.6个月,随访时检查视力及眼底,并通过光相干断层扫描（OCT）和FFA观察眼底出血和渗出吸收的情况以及CNV的闭合情况。结果同治疗前相比,末次随访时视力不变或提高的患眼为65%,视力较治疗前减退的患眼为35%。TTT治疗后1、3个月和末次随访时,OCT观察的黄斑区渗液较治疗前减少者分别占44%、52%、50%。治疗前、治疗后3个月、末次随访时,黄斑体积分别为（6.88±0.21）mm3、（6.81±0.27）mm3、（6.73±0.29）mm3,但统计学分析无显著差异。末次随访时CNV的FFA检查显示在隐匿性、典型性和微小典型性CNV闭合率分别为100%、56.25%和100%,仅4只眼荧光渗漏增加,均为典型性。结论TTT治疗高度近性视脉络膜CNV有良好的安全性和较好疗效。对隐匿性CNV的疗效可能优于典型性和微小典型性。     

经瞳孔温热疗法治疗高度近视合并中心凹下脉络膜新生血管

目的观察经瞳孔温热疗法(TTT)治疗高度近视合并中心凹下脉络膜新生血管(CNV)的疗效。方法采用半导体810红外激光对荧光素眼底血管造影(FFA)和吲哚青绿血管造影(ICGA)检查确诊的高度近视合并CNV患者18例18只眼进行治疗。初诊时平均视力为0.12。根据病灶大小选择光斑直径分别为0.8、1、2、3.0mm;能量相应为120、160、260、360mW;时间60s。治疗后每月复查1次,如有需要进行重复治疗,治疗次数1～3次。治疗后随访3～16个月。随访时检查视力、眼底出血和渗出吸收、CNV闭合情况。结果18眼治疗后均无即刻视力下降或其他不适。末诊时平均视力为0.26,与初诊视力相比,50%无变化,38.9%增加,11.1%降低。FFA联合ICGA检查显示:治疗后3个月时,渗漏消失及明显减轻6眼(42.86%),不变8眼。检眼镜眼底检查显示:治疗后3个月7只眼出血和(或)渗出部分或全部消退,6只眼出血和渗出减轻,(共占72.2%);5只眼无变化。再次治疗后4只眼吸收,随访16个月病情稳定。结论TTT治疗高度近视合并CNV有一定效果。在较长期随访中,约16.6%的CNV复发,复发患眼经再次治疗仍有好转。     

经瞳孔温热疗法治疗老年性黄斑变性中心凹下新生血管

目的探讨经瞳孔温热疗法(transpupillarythermotherapy,TTT)治疗老年性黄斑变性中心凹下新生血管的安全性及疗效。方法应用810nm激光对53例(62眼)经FFA或ICG确诊的AMD黄斑中心凹下CNV进行TTT治疗。每个光斑的照射时间为60s,激光能量为120~150mW/mm光斑直径。以矫正视力、眼底及FFA改变评价疗效。末次治疗后随诊3~15月,平均7.5月。结果末诊时,62眼共接受151次TTT治疗,平均治疗2.4次。视网膜出血完全吸收者46眼(74.19%),大部分吸收者5眼(8.06%),部分吸收者5眼(8.06%),复发性出血者6眼(9.68%)。视力提高者16眼(25.81%),不变者42眼(67.74%),下降者4眼(6.45%);其中视力低于0.1者30眼(48.39%),0.1~0.3者27眼(43.55%),>0.3者5眼(8.06%)。结论TTT是一种安全的治疗AMD黄斑中心凹下CNV的方法,能有效地促进视网膜出血吸收和CNV癍痕化,使大部分患者的视力保持稳定,但对视力的提高作用不明显。     

经瞳孔温热疗法治疗老年性黄斑变性合并中心凹下脉络膜新生血管

目的 观察经瞳孔温热疗法（TTT）治疗老年性黄斑变性（AMD） 合并中心凹下脉络 膜新生血管（CNV）的疗效。 方法 采用半导体810红外激光对荧光素眼 底血管造影（FFA）和吲哚青绿血管造影(ICGA)检查确诊的AMD合并CNV患者47例51只眼进行治疗。其中，隐匿型CNV40例42只眼,经典型CNV7例9只眼；初诊时平均视力为0.12。根据病灶大小选择光斑直径分别为0.8、1、2、3.0 mm；能量相应为120、160、260、360 mW；时间60s。治疗后 每1个月随访复查1次，如有需要，进行重复治疗，治疗次数1~3次。治疗后随访3~33个月，平均随访时间10个月。随访时检查视力、眼底出血和渗出吸收、CNV闭合情况。 结果 治疗眼治疗后均无即刻视力下降或其他不适。末诊时平均视力为0.16，与初诊视力相比，68.6 2%无变化，25.53%增加，7.84%降低。FFA联合ICGA检查显示：治疗后3个月时，隐匿型CNV闭 合率为42.86%, 经典型CNV闭合率为22.22%；6个月时，隐匿型CNV闭合率为73.81%，经典型 CNV闭合率为66.67%。检眼镜检查显示：治疗后3个月，隐匿型CNV42只眼中，出血和（或）渗出部分或全部吸收，并有厚薄不等的机化瘢痕形成；经典型CNV9只眼中7只眼出血和渗出 减轻；1只眼有新出血。治疗后6个月，27只隐匿型CNV眼中，3只眼又见新出血，其中2只眼较快吸收，保持至12个月时无变化；5只经典型CNV眼中，2只眼有新出血，再次治疗后吸收 ，随访16个月病情稳定。19只隐匿型CNV眼随访至6个月以上，5只眼出血消失，5只眼有新出血 。6个月以上的随访中，共有8只眼可见新出血，其CNV复发率占15.6％。 结论 TTT治疗AMD 合并经典型或隐匿型CNV均有一定效果。在较长期随访中,约15.6%的CNV复发，复发患眼经再次治疗仍有好转。 （中华眼底病杂志，2004，20：280-284）     

经瞳温热疗法治疗湿性年龄相关黄斑变性的疗效观察

目的：探讨经瞳温热疗法（transpupillary thermotherapy,TTT）治疗湿性年龄相关黄斑变性（age-related macular degeneration,ARMD）的初步疗效.方法：对9例14眼经眼底检查、荧光素眼底血管造影（fundus fluorescein angiography,FFA）和吲哚菁绿眼底血管造影（indocyanine green angiography,ICGA）确诊为湿性ARMD（12眼为隐匿型、2眼为经典型）的患眼行TTT治疗.根据脉络膜新生血管膜（choroidal neovascular membrane,CNV）的范围选择不同的光斑大小和能量,术后对眼底改变、视力、眼底血管造影复查,随访1～22（平均11.67）mo,以观察疗效.结果：经TTT治疗后,至末次复查时11眼（79%）出血、水肿、渗出消失、病灶斑痕化,3眼（21%）的出血、水肿、渗出明显减轻.5位患者的8眼患眼有TTT后的FFA及ICGA复查,显示其中6眼的原病灶渗漏消失、CNV消退,2眼的渗漏明显减轻.治疗后视力提高的有4眼（29%）,稳定的有7眼（50%）,下降的有3眼（21%）.除2位患者的2只患眼（14%）分别在第一次治疗后的第4和第5mo经造影复查后,接受了原病灶的再次TTT外,其余患眼（86%）均只进行了一次TTT.结论：TTT对湿性ARMD有较明确的疗效,经济安全,其远期疗效需更多病例观察.     

Polypoidal choroidal vasculopathy coexisting with exudative age-related macular degeneration

Purpose To report two cases that had polypoidal choroidal vasculopathy (PCV) coexisting with choroidal neovascularization (CNV) of exudative age-related macular degeneration (AMD). Methods Both of the patients underwent color photographs, fluorescein and indocyanine green (ICG) angiography. Results On fundus examination, a grayish lesion in the foveal area, reddish-orange lesions and hemorrhagic retinal pigment epithelial detachments (PED) in the inferotemporal vascular arch were disclosed in the left eye of a patient, and macular scarring was observed in the fellow eye. ICG angiography revealed a typical branching vascular network and polyp-like aneurysmal dilations at terminals of branches in the inferotemporal vascular arcade and a well-demarcated hyperfluorescent area of CNV in the fovea in the left eye, and staining of macular scarring was present in the fellow eye. On fundus examination of the right eye of the other patient a gray–yellow lesion at the fovea, reddish-orange lesions in the extramacula were noted, and diffuse drusens were present in the fellow eye. ICG angiography revealed scattered polyp-like aneurysmal dilations without identifiable continuous branching vascular network in the extramacula, and a well-demarcated hyperfluorescence area of CNV in the fovea. Conclusions PCV can coexist with exudative AMD in some patients and the polypoidal lesions may less involve in the fovea than CNV. Evidence of AMD are present meanwhile in the fellow eyes these patients.     

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension

Purpose To report vision and safety outcomes up to 5 years from an extension of the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Investigation evaluating verteporfin therapy in patients with subfoveal choroidal neovascularization (CNV) in age-related macular degeneration.Methods Patients who completed the 2-year randomized, placebo-controlled portion of the TAP Investigation could participate in the open-label extension study for an additional 3 years. Patients in the study extension received open-label verteporfin therapy in the study eye, fellow eye or both eyes, irrespective of original treatment assignment to placebo or verteporfin, if leakage from CNV was evident on fluorescein angiography. Follow-up visits occurred at 3-month intervals through to month 48, with a final follow-up visit at month 60.Results Of the 402 verteporfin-treated patients in the randomized trials, 320 (80%) enrolled in the extension study; 193 (60%) of these completed the extension study up to 5 years. Patients received an average of approximately two treatments during the 3 years of the extension study. Seventy-seven (62%) of the 124 verteporfin-treated patients with predominantly classic lesions at baseline who enrolled in the extension completed the month 60 examination. Twenty-six (34%) of these 77 patients had lost 3 or more lines of visual acuity by month 24 and 27 (35%) had lost this amount of vision by month 60; the mean change in visual acuity from baseline was also similar at the month 24 and month 60 examinations (−1.5 and −1.6 lines, respectively). When visual acuity results were examined for all extension patients who received verteporfin at baseline, regardless of baseline lesion composition and extension study completion status, a similar pattern of visual acuity stabilization was evident. Few additional instances of infusion-related back pain or photosensitivity reactions were reported from month 24 to month 60. No additional safety issues were noted after bilateral treatment.Conclusions Vision outcomes remained relatively stable from month 24 to month 60 even though the treatment rate was low during this period. The TAP Study Group identified no new safety concerns to preclude repeating verteporfin therapy as described in this study through 5 years.Reprint requests: Novartis Ophthalmics Medical Affairs, One Health Plaza, Building 104, East Hanover, NJ 07936, USAFinancial/proprietary interest: financial interests of Writing Committee members, who bear author responsibility for this report, are listed at the end of this articleA complete list of the participants in the Treatment of Age-related Macular Degeneration Study Group is available in Arch Ophthalmol 1999; 117:1329–1345, with updates in Arch Ophthalmol 2001;119:198–207     

One-year results after radiotherapy of choroidal neovascularization in age-related macular degeneration

Summary Choroidal neovascularization (CNV) associated with age-related macular degeneration is the major cause of legal blindness in Europe and the USA in patients aged more than 65 years, but Chakravarthy et al. has reported that radiotherapy has a beneficial effect on visual acuity. Methods: Since March 1996 we have treated 56 patients in cooperation with the Department of Radiotherapy at the Technical University in Munich. The total dose with external beam radiotherapy was 16 Gy in 8 fractions, delivered through an anterior oblique axis to spare the lens. Before the treatment and 3, 6 and 12 months after therapy, we performed a standardized visual acuity and contrast-sensitivity test (ETDRS, Pelli Robson Chard) and fluorescin angiography 6 and 12 months after therapy. Results: Twenty-five angiograms showed well-defined CNV and 31 not well-defined CNV. Six months after the treatment 15 patients had stable visual acuity within one line. Twenty-seven patients had lost more than one line of visual acuity. There was no difference between well and not well defined CNV's. One year after treatment the visual acuity remained stable within one line in 4 patients, no patient had an increase of two lines or more and 17 patients lost more then 2 lines of vision. We saw no side effects other than sicca symptoms in 3 patients. Conclusion: In our opinion, these results do not show that radiation treatment has a real beneficial effect on visual acuity. Further randomized studies are needed to demonstrate the efficiency of this treatment for choroidal neovascularization in AMD.      

Multifocal electroretinogram findings after intravitreal bevacizumab injection in choroidal neovascularization of age-related macular degeneration

Purpose

To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD).

Methods

Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG.

Results

The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection.

Conclusions

There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.     

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

BACKGROUND: Anti-vascular endothelial growth factor (anti-VEGF) agents have been shown to be effective in the treatment of neovascular age-related macular degeneration (AMD). Efficacy and safety of intravitreally administered bevacizumab (Avastin), a humanized monoclonal anti-VEGF, was assessed in minimally classic and occult subfoveal choroidal neovascularization (CNV) due to AMD. METHODS: A prospective interventional study was carried out. Bevacizumab (1.25 mg) was administered intravitreally on a 6-week basis until macular edema, subretinal fluid, and/or pigment epithelial detachment had resolved. Administration was repeated in case of relapse. Ophthalmic evaluations included a complete ophthalmic examination, measurement of the visual acuity (VA), optical coherence tomography, and fluorescein angiography. Main outcome measures were the changes between baseline and last follow-up visit in best-corrected VA, central foveal thickness (CFT) and total macular volume (TMV). RESULTS: From 102 patients [mean age (range) 74.8 (61-85) years], 102 eyes were included. Median (range) duration of follow-up was 18 (6-24) weeks. Statistically significant changes from baseline were observed in best-corrected VA [increase of 1.29 lines (P=0.001)], CFT [reduction of 56 microm (P=0.01)] and TMV [reduction of 0.80 mm(3) (P<0.0001)]. Positive results were obtained in 65/102 (64%) patients after two to three injections as a mean. In a substantial proportion of patients (38%) followed up for at least 18 weeks, recurrence of leakage requiring additional injections was observed. Treatment was well tolerated; two pigment epithelium rips and ten posterior vitreous detachments were reported. CONCLUSIONS: Short-term results suggest that intravitreally administered bevacizumab (Avastin) is effective in minimally classic and occult CNV due to AMD. Significant improvements in VA, CFT and TMV were obtained and maintained during follow-up. In some patients, however, recurrence of leakage requiring additional intravitreal injection occurred. Maintenance of the effect of bevacizumab and its safety after repeated and prolonged administration have to be investigated in well-controlled studies.     

经瞳孔温热疗法治疗渗出型老年性黄斑变性合并中心凹下脉络膜新生血管

目的 观察经瞳孔温热疗法(TTT)治疗渗出型老年性黄斑变性(AMD)合并中心凹下脉络膜新生血管(CNV)的疗效.方法 回顾分析经TTT治疗的渗出型AMD患者41例44只眼的临床资料.所有患者均经荧光素眼底血管造影(FFA)检查确诊.其中,隐匿性CNV24例26只眼,典型性CNV12例12只眼,微小典型性CNV5例5只眼.采用810 nm半导体激光进行TTT治疗.根据病灶大小选择光斑直径范围1.20～3.00 mm,能量范围160～400 mw,时间60 s.治疗次数1～3次.平均治疗1.48次,治疗后随访3～24个月,平均随访10.80个月.末次随访者40例42只眼.分别以治疗后1、3个月及末次随访时视力、眼底、FFA及光相十断层扫描(OCT)检查结果作为患眼视功能及病灶变化的观察指标,对比观察治疗前后视力改变、眼底出血渗出吸收、CNV闭合情况.结果 末次随访的42只眼中,视力不变或提高者35只眼,占83.34%;视力较治疗前减退者7只眼,占16.67%.OCT检查显示,治疗后1、3个月和末次随访时黄斑区渗液者减少率分别为79.50%、86.40%和88.10%.治疗后3个月,所有患眼黄斑容积较治疗前显著减少,差异有统计学意义(t=1.96,P=0.01);但治疗后1个月和末次随访时黄斑容积较治疗前相比,差异无统计学意义(t=1.17,0.92;P=0.19,0.83).FFA检查显示,末次随访时隐匿性、典型性和微小典型性CNV的闭合率分别为79.16%、46.15%和60.00%.仅6只眼渗漏较治疗前增加.其中,典型性CNV 5只眼,微小典型性CNV1只眼.结论 TTT治疗渗出型AMD合并典型性、隐匿型及微小典型性CNV均有一定效果.     

新生血管性年龄相关性黄斑变性药物治疗的进步和展望

年龄相关性黄斑变性( AMD)已成为老龄人口视力丧失的主要原因,随着老龄化的发展,AMD已经成为严重的公共卫生问题.其中,湿性AMD以脉络膜新生血管(CNV)为主要特征,病情进展迅速,对视力危害严重,一直以来,临床上却没有切实有效的治疗方法.近20年,随着对疾病治疗的探索,针对CNV的治疗成为关注的焦点,从实验室到临床,针对新生血管生成的靶向治疗研究给湿性AMD的药物治疗带来了新的希望,有望大大减少湿性AMD的致盲率.总结临床前沿科研结果,介绍湿性AMD的最新治疗进展.